Cancer research at Duke is an interactive and dynamic enterprise that spans the School of Medicine and includes other Duke schools. Eleven major research programs have significant peer-reviewed funding and are operationally supported by DCCI administration and communication activities. The DCCI serves this central role, which helps to facilitate interprogrammatic as well as intraprogrammatic interactions of the research program members. In addition, exciting discoveries are identified early by the DCCI and are supported to facilitate entry into the pre-clinical development pathways and to their eventual use in clinical trials. In addition, the ability of investigators to take observations in the clinic back to the laboratory is facilitated by the DCCI. The DCCI is central to the complex coordination of activities essential to contemporary cancer research and makes possible many activities that would be far too complex to organize without the support of the CCSG. The DCCI was recently reorganized to have institute status at Duke. The DCCI differs from the former DCCC because it incorporates newly added institutional resources and infrastructure provided by significant investments in clinical trials support, as well as recognizes the oversight provided to specific components of departments and the health system. The formal institute status at Duke enhances communication and cooperation among the basic science departments with a significant focus on cancer and both the in-patient and out-patient cancer clinical services. The former Institutional Steering Committee, now named the Cancer Medicine Leadership Council (CMLC), has representatives from all of the relevant Duke clinical and research units (health system, hospital, departments, centers and institutes). All major strategic and operational decisions (e.g. expansion of clinical or research faculty within any of these units; capital investments in facilities or instrumentation; leadership appointments) that fall within the current scope of authority of any of these entities are presented and discussed within this council. Because of the significant administrative changes implemented in the past year, we have refrained for implementing our formal strategic planning until approval of the institute status of the DCCI. We are currently engaged in a strategic planning process being led by Elaine Kuttner of Cambridge Concord Associates and will have our Strategic Plan draft available at the time of the CCSG site visit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-38
Application #
8379518
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
38
Fiscal Year
2012
Total Cost
$51,492
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955
Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766
Abdi, Khadar; Lai, Chun-Hsiang; Paez-Gonzalez, Patricia et al. (2018) Uncovering inherent cellular plasticity of multiciliated ependyma leading to ventricular wall transformation and hydrocephalus. Nat Commun 9:1655
Hudson, Kathryn E; Rizzieri, David; Thomas, Samantha M et al. (2018) Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study. Br J Haematol :

Showing the most recent 10 out of 513 publications